Pacific Biosciences of California, Inc. (NasdaqGS: PACB)
Health Care · Life Sciences Tools & Services · US
$2.25
-3.43% today · +52.3% 1Y
Pacific Biosciences of California, Inc. (NasdaqGS: PACB) operates in the Life Sciences Tools & Services industry within the Health Care sector. The company is valued at $724.24M and employs 485 people.
Over the last twelve months the share price has gained 52.3%, trading between 1.07 and 3.44.
Tweenvest scores Pacific Biosciences of California, Inc. across four factors: quality 38/100, value 50/100, growth 39/100. Its strongest factor is value.
PACB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $724.24M
- Revenue (TTM)
- $159.27M
- P/E
- —
- EPS
- -0.43
- Dividend yield
- —
- Beta (5Y)
- 2.19
- 52-week high
- $3.44
- 52-week low
- $1.07
- Avg volume (3M)
- —
- Shares outstanding
- 310.83M
- Employees
- 485
- Next earnings
- —
About Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.
- ISIN
- US69404D1081
- Founded
- 2000
- Listed since
- Oct 27, 2010
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Life Sciences Tools & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Suven Life Sciences LimitedBSE: 530239 | $825.52M | Rs282.75 | -8.35% |
| Shanghai Obio Technology (Group) Corp., Ltd.SHSE: 688238 | $807.40M | CN¥8.58 | -3.05% |
| Boji Medical Technology Co.,Ltd.SZSE: 300404 | $806.99M | CN¥14.11 | -4.21% |
| Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.SZSE: 301096 | $739.13M | CN¥45.65 | -7.40% |
| Mesa Laboratories, Inc.NasdaqGS: MLAB | $713.53M | $127.51 | 0.00% |
| Cytek Biosciences, Inc.NasdaqGS: CTKB | $705.81M | $5.43 | +1.31% |
| Shanghai Model Organisms Center, Inc.SHSE: 688265 | $702.87M | CN¥60.93 | -6.23% |
| OmniAb, Inc.NasdaqGM: OABI | $696.42M | $4.90 | +2.30% |
Figures last refreshed Oct 11, 2026.